Day One Biopharmaceuticals' Q1'25 sales grew modestly, but Q2 2025 earnings could spark movement. Read why I currently rate ...

As shown in the following overview of Whitehawk’s portfolio and ADC technology platform: The company’s three lead candidates target different cancer-associated proteins: HWK-007 targeting Protein ...

We recently published a list of 10 Best Low Priced Biotech Stocks to Buy Now. In this article, we are going to take a look at ...

The company has a robust strategy for long-term growth, which includes the promising early-stage development of its anti-PTK7 ADC and a focus on overcoming physician conservatism in pediatric ...

In addition, it has also started testing DAY301, a new antibody-drug that targets PTK7. The drug is in Phase Ia/b dose escalation trials, meanwhile, the company struck a licensing deal with Ipsen ...

and progress in ADC programs targeting Ly6E and PTK7, showcasing advancements in technology and therapeutic designs. Management reaffirmed their guidance on pipeline priorities, with the IND for ...

Session Title: Antibody-Based Cancer Therapeutics 1 Protein Tyrosine Kinase 7 (PTK7) over expression across multiple tumor types including breast, digestive tract, and lung cancers, makes it an ...

To enable optimal targeting, and overcome limitations of prior PTK7 ADCs, Zymeworks identified a lead biparatopic antibody displaying improved binding and receptor-mediated internalization ...

Protein Tyrosine Kinase 7 (PTK7) over expression across multiple tumor types including breast, digestive tract, and lung cancers, makes it an attractive target for ADCs. To enable optimal ...

Session Title: Antibody-Based Cancer Therapeutics 1 Protein Tyrosine Kinase 7 (PTK7) over expression across multiple tumor types including breast, digestive tract, and lung cancers, makes it an ...